| 000 | 01579 a2200409 4500 | ||
|---|---|---|---|
| 005 | 20250514164524.0 | ||
| 264 | 0 | _c20040323 | |
| 008 | 200403s 0 0 eng d | ||
| 022 | _a0946-1965 | ||
| 024 | 7 |
_a10.5414/cpp41616 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHeim, M | |
| 245 | 0 | 0 |
_aAntitumor effect and potentiation or reduction in cytotoxic drug activity in human colon carcinoma cells by the Raf kinase inhibitor (RKI) BAY 43-9006. _h[electronic resource] |
| 260 |
_bInternational journal of clinical pharmacology and therapeutics _cDec 2003 |
||
| 300 |
_a616-7 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents _xpharmacology |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 |
_aBenzenesulfonates _xadverse effects |
| 650 | 0 | 4 |
_aCarcinoma _xpathology |
| 650 | 0 | 4 |
_aCell Cycle _xdrug effects |
| 650 | 0 | 4 |
_aColonic Neoplasms _xpathology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aNiacinamide _xanalogs & derivatives |
| 650 | 0 | 4 | _aPhenylurea Compounds |
| 650 | 0 | 4 |
_aProto-Oncogene Proteins c-raf _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aPyridines _xadverse effects |
| 650 | 0 | 4 | _aSorafenib |
| 650 | 0 | 4 | _aTumor Cells, Cultured |
| 700 | 1 | _aSharifi, M | |
| 700 | 1 | _aHilger, R A | |
| 700 | 1 | _aScheulen, M E | |
| 700 | 1 | _aSeeber, S | |
| 700 | 1 | _aStrumberg, D | |
| 773 | 0 |
_tInternational journal of clinical pharmacology and therapeutics _gvol. 41 _gno. 12 _gp. 616-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.5414/cpp41616 _zAvailable from publisher's website |
| 999 |
_c14423661 _d14423661 |
||